The U.S. Food and Drug Administration will hold off on approving Novo Nordisk’s diabetes medication Tresiba, a long-acting insulin, until the company conducts extra tests to address heart risks.
A Reuters story says over-eating and lack of exercise have created an “epidemic” of type 2 diabetes, creating a high demand for treatment.
But the FDA is wary of new diabetes treatments, in light of controversy over GlaxoSmithKline’s Avandia pill. According to Reuters, ...
continue reading...